Showing results (381-390 of 4,039) with videos related to

Sort By:
Pageof 404
Pharmacoepidemiology and Drug Safety|January 17, 2025
Impact of Lookback Duration on the Performance of a Claims-Based Frailty Proxy in Women With Stage I-III Breast CancerEmilie D Duchesneau, Til Stürmer, Katherine Reeder-Hayes, et al.
Pharmacoepidemiology and Drug Safety|January 8, 2025
More Drugs and Fewer Strokes? Time Trends in CVD Medication and Incidence of Stroke With German Health Insurance DataLieselotte Mond, Siegfried Geyer, Juliane Tetzlaff, et al.
Pharmacoepidemiology and Drug Safety|January 8, 2025
Success of the German Cystic Fibrosis RegistryLutz Naehrlich, Manuel Burkhart,
Pharmacoepidemiology and Drug Safety|January 8, 2025
Use of Causal Framework to Evaluate Effect of Abuse Deterrent Properties of Extended-Release Oxycodone on Tampering in a Real-World SettingsKarilynn M Rockhill, Hannah Burkett, Richard Dart, et al.
Pharmacoepidemiology and Drug Safety|January 13, 2025
Core Concepts: Self-Controlled Designs in PharmacoepidemiologySophie H Bots, Jeremy Brown, Angel Y S Wong, et al.
Pharmacoepidemiology and Drug Safety|January 13, 2025
A Descriptive Comparative Analysis of Safety Concerns Outlaid in the Risk Management Plans of the European Union and JapanTeruyuki Honda, Mamoru Narukawa
Pharmacoepidemiology and Drug Safety|March 25, 2025
Antibiotics and Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome: Analysis of Brazilian Pharmacovigilance RegistriesMarcelo Bueno de Camargo, Inês Ribeiro-Vaz, Cristiane de Cássia Bergamaschi, et al.
Pharmacoepidemiology and Drug Safety|March 24, 2025
Prevalence Trends and Patterns of Perinatal ADHD Stimulant Medication Use in British Columbia, CanadaAmanda Nitchske, Ali Salmanpour, Paramdeep Kaur, et al.
Pharmacoepidemiology and Drug Safety|December 19, 2024
Barriers and Facilitators on Pharmacovigilance Practice Among Pharmacists in Metro Manila, PhilippinesRogie Royce Carandang, Justin Gabriel Gumop-As, Salve Regina Andoloy, et al.
Pharmacoepidemiology and Drug Safety|December 3, 2024
Determining Targets for Antiretroviral Drug Concentrations: A Causal Framework Illustrated With Pediatric Efavirenz Data From the CHAPAS-3 TrialMichael Schomaker, Paolo Denti, Andrzej Bienczak, et al.
Pageof 404